TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03098524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTV arm)
Description: During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No ventilation (noV arm)
Description: During cardiopulmonary bypass, no mechanical ventilation is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuver
Description: An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lung recruitment manoeuver
Description: An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit).
Study: NCT03128489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
Study: NCT01255306

Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day

Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day

Intervention type: DRUG
Intervention: Local medical treatment of raised intraocular pressure
Description: In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.
Study: NCT00529698

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biologically active recombinant Tat protein

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biologically active recombinant Tat protein
Study: NCT01511510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.05 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.15 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.25 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution Q24 hours for 14 days
Study: NCT03792165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The normal human movement will be recorded and than the patients will be watched them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study: NCT02521389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PWT-143
Description: phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PWT-143
Description: phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
Study: NCT04605939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study: NCT03297333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: The aerobic interval training group
Study: NCT04748692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local exercise therapy
Description: The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manual therapy
Description: The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
Study: NCT01760187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Study: NCT03685058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light curable resin modified glass ionomer varnish
Description: Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-of-care preventive measures
Description: Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard-of-care preventive measures
Description: Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
Study: NCT03678051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard of care residential treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard of care residential treatment
Study: NCT00085917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose pegylated interferon with weight based Ribavirin
Description: pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose pegylated interferon alfa -2a and ribavirin
Description: pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
Study: NCT01206790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET
Description: Narrative Exposure Therapy for traumatized survivors of organized violence
Study: NCT04197141

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally-fractionated WPRT
Description: Total dose: 45 Gy in 25 fractions WPRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated WPRT
Description: Total dose: 25 Gy in 5 fractions WPRT
Study: NCT00211874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-management
Description: bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
Study: NCT03347812

Intervention type: PROCEDURE
Intervention: Endovascular Aortic Repair
Description: Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.

Intervention type: PROCEDURE
Intervention: Total Arch Replacement
Description: A kind of open surgery is performed for the replacement of total aortic arch.
Study: NCT01597011

Intervention type: PROCEDURE
Intervention: Fibrin Sealant
Description: Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,

Intervention type: PROCEDURE
Intervention: Tissue-penetrating mesh-fixation
Description: Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
Study: NCT02037451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhythmic auditory stimulation
Description: Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
Study: NCT01948869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix II (BAY81-2996)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoenix I (BAY81-2996)
Study: NCT01385267

Intervention type: PROCEDURE
Intervention: aspiration of amniotic fluid
Description: a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
Study: NCT00603733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA (5-Aminosalicylate)
Description: 500 mg tablet (modified extended release)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ASA (5-Aminosalicylate)
Description: 500 mg tablet
Study: NCT04712357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C 500 MG Oral Tablet
Description: Vitamin C 500 MG per day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxyl fumarate 300 MG Oral Tablet
Description: Tenofovir disoproxyl fumarate 300 MG per day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet
Description: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
Study: NCT02062398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Reprieve System
Description: BlueWind Medical neurostimulator for the treatment of neuropathic pain
Study: NCT03411668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBP Educational Programme
Description: The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
Study: NCT00961870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups.
Study: NCT04208646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal progenitor cells
Description: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal progenitor cells
Description: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No mesenchymal progenitor cells
Description: No mesenchymal progenitor cells for intra- articular use
Study: NCT00947843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + pregrel (Clopidogrel resinate)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin + placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + plavix (Clopidogrel bisulfate)
Study: NCT00583661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCOR Pediatric
Description: Extracorporeal Ventricular Assist Device
Study: NCT01817114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Remote Ischemic Conditioning (AutoRIC) device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auto Remote Ischemic Conditioning (AutoRIC) device
Study: NCT01744457

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of tear film osmolarity with the TearLab® instrument

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of tear film osmolarity with the TearLab® instrument

Intervention type: OTHER
Group type: OTHER
Intervention: Schirmer I test

Intervention type: OTHER
Group type: OTHER
Intervention: Schirmer I test

Intervention type: OTHER
Group type: OTHER
Intervention: Tear break up time

Intervention type: OTHER
Group type: OTHER
Intervention: Tear break up time

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Quality Analysis System
Description: Measurement of the objective scattering index (OSI)

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Quality Analysis System
Description: Measurement of the objective scattering index (OSI)

Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Surface Disease Index

Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Surface Disease Index
Study: NCT00587015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAT-8015
Description: The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60...μg/kg until toxicity supervenes.
Study: NCT03657212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Description: The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
Study: NCT01709214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol (GRT6005) Low-Dose Range
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol (GRT6005) High-Dose Range
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Study: NCT02158234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 15 mg/m\^2 prior to each fraction
Study: NCT01709214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: Capsules containing oxycodone CR 10 or 20 milligrams
Study: NCT00418210

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
Description: Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
Study: NCT02403713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol BAI
Description: Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI without spacer
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI with spacer
Description: Fluticasone/Formoteral 125/5µg pMDI with spacer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI without spacer low dose
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
Study: NCT03239886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imatinib discontinuation
Description: imatinib discontinuation
Study: NCT03326609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
Study: NCT04282070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Maximum 6 cycles for combined therapy.
Study: NCT01753388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liberty Stent
Study: NCT03281447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse navigation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care coordination
Study: NCT02690324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive stress (serial 7)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive stress (serial 7)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive stress (serial 7)
Study: NCT01989754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily for 156 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study: NCT03326609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)